The rise of Sildenafil initially fueled a surge for major pharmaceutical companies, but recent changes present a murky scenario for investors. Off-patent versions are eroding revenue, and ongoing legal battles add https://ihannahwxk839159.blog-gold.com/58520234/sildenafil-and-pharma-a-risky-bet